|
Tuesday
10 July |
09:15 |
Registration and coffee |
|
|
09:50 |
Welcome |
|
Graham Russell (Oxford, UK) |
|
|
Cellular regulation of bone
metabolism |
Chairs: Jack
Martin (Melbourne, Australia) & David
Roodman (Pittsburgh, USA) |
|
|
10:00 |
Interactions with the immune system in the
regulation of bone function |
|
Matt
Gillespie (Melbourne, Australia) |
|
|
10:30 |
The role of osteocytes in the regulation of
bone function |
|
Brendon
Noble (Edinburgh, UK) |
|
|
11:00 |
Bone as a metabolic regulator |
|
Patricia
Ducy (New York, USA) |
|
|
11:30 |
Break |
|
|
Anabolic agents for bone |
Chairs: Greg
Mundy (Nashville, USA) &
Jonathan Reeve (Cambridge, UK) |
|
|
11:45 |
Progress with the development of anabolic
agents for bone |
|
Roland
Baron (New Haven, USA) |
|
|
12:15 |
Understanding mechanisms of the anabolic action
of PTH |
|
David
Dempster (West Haverstraw, USA) |
|
|
12:45 |
Lunch |
|
|
Novel regulators of bone |
Chairs: Roger Francis
(Newcastle upon Tyne, UK) & Michael
Whyte (St Louis, USA) |
|
|
14:00 |
Strontium – mechanisms of action. Experimental
and clinical effects |
|
René
Rizzoli (Geneva, Switzerland) |
|
|
14:30 |
Is there a future for vitamin D analogues
in osteoporosis? |
|
Roger
Bouillon (Leuven, Belgium) |
|
|
15:00 |
Tea |
|
|
Novel regulators of bone continued |
Chairs: Matt
Gillespie (Melbourne, Australia) & Mike
Rogers (Aberdeen, UK) |
|
|
15:30 |
Cannabinoids and bone: friend or Foe? |
|
Aymen
Idris (Edinburgh, UK) |
|
|
15:50 |
Hydrogen ion sensing |
|
Tim
Arnett (London, UK) |
|
|
16:10 |
Purinurgic Pathways |
|
Jim
Gallagher (Liverpool, UK) |
|
|
16:30 |
Thyroid stimulating hormone (TSH) may serve
as a bone anabolic agent for postmenopausal osteoporosis |
|
Kuber
Sampath (Framingham, USA) |
|
|
16:50 |
BMPs in 2007 |
|
Slobodan
Vukicevic (Zagreb, Croatia) |
|
|
17:20 |
Close |
|
|
19:00 |
Dinner |
|
|
20:15 |
Oxford walking tour |
|
|
|
|
Wednesday
11 July |
Techniques and imaging |
Chairs: Richard
Eastell (Sheffield, UK) & Morten
Karsdal (Herlev, Denmark) |
|
|
09:00 |
Structural genomics and drug discovery |
|
Udo
Oppermann (Oxford, UK) |
|
|
09:30 |
Advances in the imaging of bone |
|
Ralph
Müller (Zurich, Switzerland) |
|
|
10:00 |
New approaches to genetics |
|
Matt Brown (Brisbane, Australia)
|
|
|
10:30 |
The development of markers in bone |
|
Jude
Onyia (Indianapolis, USA) |
|
|
11:00 |
Coffee |
|
|
New therapeutic areas and approaches |
Chairs: Roger
Bouillon (Leuven, Belgium) & Paul
Wordsworth (Oxford, UK) |
|
|
11:45 |
Current therapies in inflammatory arthritis |
|
Paul
Emery (Leeds, UK) |
|
|
12:15 |
Current concepts in bone oncology and their
therapeutic potential |
|
Greg
Mundy (Nashville, USA) |
|
|
12:45 |
Lunch |
|
|
New therapeutic areas and approaches
continued |
Chairs: Tim
Arnett (London, UK) & Socrates
Papapoulos (Leiden, Netherlands) |
|
|
14:00 |
NHR (nuclear hormone receptor) modulators:
SERMs, SARMs and
vitamin D |
| |
Henry Bryant (Indianapolis,
USA) |
|
|
14:30 |
From the discovery of OPG and RANKL to the
pursuit of sclerostin: molecules regulating skeletal physiology
|
|
Scott
Simonet (Thousand Oaks, USA) |
|
|
15:10 |
The RANK ligand system – Clinical potential |
|
Nathalie
Franchimont (Zug, Switzerland) |
|
|
15:40 |
Tea |
|
|
New therapeutic areas and approaches
continued |
Chairs: Roland
Baron (New Haven, USA) & Philippa
Hulley (Oxford, UK) |
|
|
16:00 |
New targets for bone anabolics – sclerostin/SOST |
|
Michaela
Kneissel (Basel, Switzerland) |
|
|
16:30 |
Vascular calcification. Pathogenic mechanisms
and opportunities for therapeutic intervention |
| |
Dwight
Towler (St Louis, USA) |
|
|
17:00 |
Close |
|
|
19:30 |
Reception and Dinner |
|
|
|
|
Thursday
12 July |
| Joint Sessions |
| Advances in the Molecular
Pharmacology and Therapeutics of Bone Disease |
| and International Symposium
on Paget’s Disease |
|
08:30 |
Welcome and introduction |
|
Chairs: Graham Russell (Oxford,
UK) & Cyrus Cooper (Southampton, UK) |
|
|
08:40 |
Evolution of treatments for Paget’s Disease
and osteoporosis |
|
Paul Miller (Lakewood, USA) |
|
|
Bisphosphonate actions |
Chairs: Hal Ebetino
(Cincinnati, USA) & Greg
Mundy (Nashville, USA) |
|
|
09:10 |
The molecular mechanism of bisphosphonates |
|
Mike
Rogers (Aberdeen, UK) |
|
|
09:35 |
Alternate pathways of action of bisphosphonates
on bone cells |
|
Teresita
Bellido (Little Rock, USA) |
|
|
10:00 |
The biology of gamma-delta T cells and opportunities
for pharmacological intervention |
|
Andrew
Sewell (Cardiff) |
|
|
10:25 |
Coffee |
|
|
Therapeutic opportunities of
bisphosphonates in osteoporosis and other disorders |
Chairs: Peter Selby
(Manchester, UK) & Ian
Reid (Auckland, New Zealand) |
|
|
10:50 |
Effect of zoledronic acid 5 mg IV once yearly
on hip, spine, and non-spine fractures in patients with postmenopausal
osteoporosis |
|
Richard
Eastell (Sheffield, UK) |
|
|
11:20 |
Hip fracture: What are the reasons and opportunities
for pharmacologic intervention? |
|
Kenneth
Lyles (Durham, USA) |
|
|
11:50 |
Potential roles of bisphosphonates in
orthopaedic applications: aid in fracture healing, osteonecrosis
and implant fixation |
|
David
Little (Sydney, Australia) |
|
|
12:20 |
Potential roles of bisphosphonates in osteoarthritis |
|
Roy
Altman (Miami, USA) |
|
|
12:50 |
Lunch |
|
|
Current controversies in bisphosphonate
therapy |
Chairs: Eugene McCloskey
(Sheffield, UK) & Paul Miller
(Lakewood, USA) |
|
|
14:00 |
Bisphosphonates and oversuppression of bone
turnover: weighing the evidence |
|
Socrates
Papapoulos (Leiden, Netherlands) |
|
|
14:30 |
Sequential treatment of bisphosphonates and
PTH: challenging current assumptions |
|
Jürg
Gasser (Basel, Switzerland) |
|
|
15:00 |
Osteonecrosis of the jaw and bisphosphonates:
an update |
|
Erik
Eriksen (Basel, Switzerland) |
|
15:30 |
Tea |
|
|
16:00 |
Oral communications |
Chairs: Erik
Eriksen (Basle,Switzerland) & David
Little (Sydney,Australia) |
|
|
16:00
P1 |
CIRCULATING CATHEPSIN K LEVELS BEFORE AND
AFTER INTRAVENOUS BISPHOSPHONATE TREATMENT IN PAGET'S DISEASE
OF BONE |
|
V De Paola, L Gennari, D Merlotti, G Martini,
F Valleggi, A Avanzati, MB Franci, MS Campagna, R Nuti |
|
|
16:05
P2 |
EFFICACY AND SAFETY OF ZOLEDRONIC ACID IN
PAGETS DISEASE OF BONE: 4 YEARS OF EXPERIENCE
|
|
A Conesa Mateos, D Rotés Sala, L Pérez
Edo, J Carbonell Abelló
Department of Rheumatology. Hospital del Mar y Esperanza.
Instituto Municipal de Asistencia Sanitaria (I.M.A.S). Universidad
Autónoma. Barcelona, Spain |
|
|
16:10
P3 |
IS PLAIN ABDOMINAL X-RAY A SENSITIVE TOOL
FOR THE SCREENING OF PAGET DISEASE OF BONE? |
|
L. Corral-Gudino, J. García-Aparicio,
S. Gómez-Castro, C.A. Montilla, J del Pino-Montes
Servicio de Reumatología. Hospital Universitario de
Salmanca, Spain |
|
|
16:15
P4 |
LONG-TERM EFFECTS OF SINGLE ZOLEDRONATE OR
NERIDRONATE INFUSION IN PAGET'S DISEASE OF BONE |
|
D Merlotti, L Gennari, F Valleggi, V De Paola,
G Martini, A Avanzati, R Nuti
Department of Internal Medicine, Endocrine-Metabolic Sciences
and Biochemistry, University of Siena, Italy |
|
|
16:20
P5 |
MANAGEMENT OF PAGET'S DISEASE OF BONE: AN
AUDIT OF CLINICAL PRACTICE IN AUSTRALIA |
|
J P Walsh[1], R Attewell[2],
M J Hooper[3], J D Wark[4], S Fletcher[5],
V Ferrari[5], J A Eisman[6]
[1]Department of Endocrinology and Diabetes, Sir
Charles Gairdner Hospital, Nedlands, WA, Australia; [2]
Covance Pty Ltd, Braddon, ACT, Australia; [3] Bone
Research Program, ANZAC Research Institute, Concord Repatriation
Hospital, The University of Sydney and Central Sydney Area
Health Service, Sydney, NSW, Australia; [4] Department
of Medicine, University of Melbourne, Royal Melbourne Hospital,
Parkville, Victoria, Australia; [5] Novartis Pharmaceuticals
Australia Pty Ltd, North Ryde, NSW, Australia; [6]
Bone and Mineral Research Program, Garvan Institute of Medical
Research, Sydney, NSW, Australia. |
|
|
16:25
P6 |
RAPID PAIN RELIEF AND CLINICAL IMPROVEMENT
WITH INTRAVENOUS ZOLEDRONIC ACID IN LOCALIZED TRANSIENT OSTEOPOROSIS
OF THE HIP |
|
Ringe JD, Dorst A, Farahmand P. Medizin. Klinik
4 (Rheumatology, Osteology)Klinikum Leverkusen, University
of Cologne,Germany |
|
|
16:30
P7 |
TREATMENT OF HUNGARIAN PATIENTS WITH PAGET'S
DISEASE OF BONE WITH ZOLEDRONIC ACID |
|
J Donath, Zs Nagy, P Gergely Jr, Gy Poor
National Institute of Rheumatology and Physiotherapy, Budapest,
Hungary |
|
|
16:35 |
Close |
|
|
19:00 |
Dinner |
|
|
